Cidara Therapeutics Inc [CDTX] stock prices are up 2.96% to $49.45 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CDTX shares have gain 135.25% over the last week, with a monthly amount glided 117.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on March 12, 2025, and set its price target to $46. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $34 on December 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on November 08, 2024. H.C. Wainwright upgraded its rating to Buy for this stock on August 14, 2024, but kept the price target unchanged to $24.
The stock price of Cidara Therapeutics Inc [CDTX] has been fluctuating between $10.14 and $56.83 over the past year. Currently, Wall Street analysts expect the stock to reach $57 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $49.45 at the most recent close of the market. An investor can expect a potential return of 15.27% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
The Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 0.30M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -357.44%, Pretax Profit Margin comes in at -614.55%, and Net Profit Margin reading is -598.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -1.31 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.74 points at the first support level, and at 44.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 50.83, and for the 2nd resistance point, it is at 52.21.
Ratios To Look Out For
It’s worth pointing out that Cidara Therapeutics Inc [NASDAQ:CDTX]’s Current Ratio is 3.87. Also, the Quick Ratio is 3.87, while the Cash Ratio stands at 3.45. Considering the valuation of this stock, the price to sales ratio is 3449.03, the price to book ratio is 4.26.
Transactions by insiders
Recent insider trading involved Mineo Chrysa, Director, that happened on Jun 02 ’25 when 2270.0 shares were purchased. Director, Mineo Chrysa completed a deal on Jun 03 ’25 to buy 1050.0 shares. Meanwhile, COO & CLO Ward Shane sold 1664.0 shares on Mar 11 ’25.
